Diagnostic Vabra (aspiration) curettage. An evaluation of the diagnostic certainty, efficacy, acceptability, indication and socio-medical importance. 1979

P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen

UI MeSH Term Description Entries
D008599 Menstruation Disturbances Variations of MENSTRUATION which may be indicative of disease. Hypomenorrhea,Menstruation Disorders,Menstruation, Retrograde,Polymenorrhea,Irregular Menses,Irregular Menstruation,Menstrual Irregularities,Menstrual Irregularity,Disorder, Menstruation,Disorders, Menstruation,Disturbance, Menstruation,Disturbances, Menstruation,Irregularity, Menstrual,Menses, Irregular,Menstruation Disorder,Menstruation Disturbance,Menstruation, Irregular,Retrograde Menstruation
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D004107 Dilatation and Curettage Dilatation of the cervix uteri followed by a scraping of the endometrium with a curette. Curettage and Dilatation,Dilatation & Curettage
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014594 Uterine Neoplasms Tumors or cancer of the UTERUS. Cancer of Uterus,Uterine Cancer,Cancer of the Uterus,Neoplasms, Uterine,Neoplasms, Uterus,Uterus Cancer,Uterus Neoplasms,Cancer, Uterine,Cancer, Uterus,Cancers, Uterine,Cancers, Uterus,Neoplasm, Uterine,Neoplasm, Uterus,Uterine Cancers,Uterine Neoplasm,Uterus Cancers,Uterus Neoplasm

Related Publications

P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
March 1990, Gynecologic oncology,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
January 1986, European journal of gynaecological oncology,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
January 1988, Acta obstetricia et gynecologica Scandinavica,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
April 1975, Danish medical bulletin,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
January 1977, Acta obstetricia et gynecologica Scandinavica. Supplement,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
March 1977, New York state journal of medicine,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
March 1974, Irish journal of medical science,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
January 1980, Annali di ostetricia, ginecologia, medicina perinatale,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
May 1975, American journal of obstetrics and gynecology,
P E Haack-Sørensen, and H Starklint, and A Aronsen, and M K Hansen, and K Kristoffersen
January 1981, Scottish medical journal,
Copied contents to your clipboard!